Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016; New Report Launched

Bangalore, Karnataka -- (SBWire) -- 04/14/2016 --Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016 report provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape. The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration

- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects

- The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Spanning over 254 pages "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016" report covers Introduction, Wet (Neovascular / Exudative) Macular Degeneration Overview, Therapeutics Development, Drug Profiles, Appendix, Methodology. The Report covered companies few are - Aciont Inc., Allergan Plc, Amakem NV, Apellis Pharmaceuticals, Inc., Apexigen, Inc., Applied Genetic Technologies Corporation, Avalanche Biotechnologies, Inc., Benitec Biopharma Limited, BIOCAD, Boehringer Ingelheim GmbH, Charlesson LLC., Chong Kun Dang Pharmaceutical Corp., Circadian Technologies Limited, Clanotech AB, Clearside BioMedical, Inc.

For more information Visit at: http://www.drugpipeline.net/global-markets-direct/wet-neovascular-exudative-macular-degeneration-pipeline-review-h1-2016

Related Reports:

Blepharitis - Pipeline Review, H1 2016; visit - http://www.drugpipeline.net/global-markets-direct/blepharitis-pipeline-review-h1-2016

Sarcoidosis - Pipeline Review, H1 2016; visit - http://www.drugpipeline.net/global-markets-direct/sarcoidosis-pipeline-review-h1-2016

Medullary Thyroid Cancer - Pipeline Review, H1 2016; visit - http://www.drugpipeline.net/global-markets-direct/medullary-thyroid-cancer-pipeline-review-h1-2016

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.